Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. The U.S. Foundayo launch is transitioning from a physician education and access-securing phase to a broad direct-to-consumer marketing phase to capture pent-up demand. Strategic business development accelerated with acquisitions of Curevo, LimmaTech, and Vaccine Company, marking a deliberate entry into the infectious disease prevention market. The acquisition of AtaiBeckley signals a strategic pivot toward rapid-acting neuroplastogens to address high unmet needs in treatment-resistant depression.